Amneal Pharmaceuticals, Inc. (AMRX)

6,12 +0,07 (+1,16%) Al cierre: 04:00PM EDT

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 08807
United States
908 947 3120
https://amneal.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 7850

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Chirag K. Patel	Co-Founder, Co-CEO, President & Director	1,71M	N/A	1967
Mr. Chintu Patel R.Ph.	Co-Founder, Co-CEO & Director	1,7M	N/A	1972
Mr. Anastasios G. Konidaris	Executive VP & CFO	1,04M	N/A	1967
Mr. Jason B. Daly Esq.	Senior VP, Chief Legal Officer & Corporate Secretary	779,06k	N/A	1974
Ms. Nikita Shah	Executive VP & Chief Human Resources Officer	848,83k	N/A	1979
Mr. Andrew S. Boyer	Executive VP & Chief Commercial Officer of Generics	1,2M	N/A	1966
Mr. Anthony DiMeo	Head of Investor Relations	N/A	N/A	N/A
Mr. Gregory Sgammato	Senior Vice President of Corporate Development	N/A	N/A	N/A
Mr. Pranav Mehta	Senior VP of Strategic Sourcing & Supply Management	N/A	N/A	N/A
Dr. Sanjay Kumar Jain Ph.D.	Chief Quality Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Gobierno corporativo

El ISS Governance QualityScore de Amneal Pharmaceuticals, Inc., a día 29 de abril de 2024, es 5. Las puntuaciones base son Auditoría: 6; Tablero: 6; Derechos de los accionistas: 4; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.